Expression of Matrix Metalloproteinases and Tissue Inhibitor of Matrix Metalloproteinases in Non-Small-Cell Lung Cancer
作者： Makoto Suzuki , Toshihiko Iizasa , Takehiko Fujisawa , Masayuki Baba , Yutaka Yamaguchi
DOI: 10.1159/000024506
关键词:
摘要: Expression of matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor metalloproteinases (TIMP)-1, and TIMP-2 was studied in non-small-cell lung cancer (NSCLC). Activity MMP-2 MMP-9 by gelatin zymography expression MMP-2, TIMP-1, mRNAs were examined 11 cell lines which included six small-cell (SCLC) lines. Localization immunohistochemistry 43 resected NSCLC (22 adenocarcinomas, 17 squamous carcinomas, 4 large carcinomas) using specific anti-human monoclonal antibodies. mRNA detected 5 (100%), 1 (20%), TIMP-1 (80%), (100%) examined. gelatinolytic activity also all five lines, whereas only one line. In patients, immunoreactivity demonstrated 19 (44%), 9 (21%), 15 (35%), 29 (67%) excised tumors, respectively. All stromal fibroblasts tumor samples stained positive for MMP-2. There a correlation between disease stage (42% I versus 88% stages II, III, IV) (p = 0.0024). Both frequently expressed TIMP-2; particular highly malignant cells surrounding fibroblasts. These findings suggest that plays more important role invasion than may have clinical relevance NSCLC.
sci-hub.st 参考文章(31)
Sato H, Sasaki T, Tanaka J, Kida Y, Seiki M, Mai M, Endo Y, Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene. ,vol. 7, pp. 77- 83 ,(1992)
James H. McKerrow, Karyn Bouhana, James T. Rutka, Jane R. Giblin, Michael E. Berens, Gerard Apodaca, Michael J. Banda, Mark L. Rosenblum, Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Research. ,vol. 50, pp. 2322- 2329 ,(1990)
Oliver Howard Beahrs, Max H. Myers, Manual for Staging of Cancer ,(1992)
W G Stetler-Stevenson, H C Krutzsch, L A Liotta, Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. Journal of Biological Chemistry. ,vol. 264, pp. 17374- 17378 ,(1989) , 10.1016/S0021-9258(18)71503-2
Gary L. Youngleib, Karen B. Rosinski, James P. Quigley, Ute M. Moll, Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells. Cancer Research. ,vol. 50, pp. 6162- 6170 ,(1990)
Danny R. Welch, Garth L. Nicolson, Motowo Nakajima, Paula N. Belloni, Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Research. ,vol. 47, pp. 4869- 4876 ,(1987)
SJ Urbanski, DR Edwards, A Maitland, KJ Leco, A Watson, AE Kossakowska, Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. British Journal of Cancer. ,vol. 66, pp. 1188- 1194 ,(1992) , 10.1038/BJC.1992.434
P. D. Brown, R. E. Bloxidge, E. Anderson, A. Howell, Expression of activated gelatinase in human invasive breast carcinoma. Clinical & Experimental Metastasis. ,vol. 11, pp. 183- 189 ,(1993) , 10.1007/BF00114976
Martha R Clarke, Rodney J Landreneau, Sydney D Finkelstein, Tsung T Wu, Paul Ohori, Samuel A Yousem, Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung Human Pathology. ,vol. 28, pp. 54- 59 ,(1997) , 10.1016/S0046-8177(97)90279-3
L. A. Liotta, K. Tryggvason, S. Garbisa, Ian Hart, C. M. Foltz, S. Shafie, Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. ,vol. 284, pp. 67- 68 ,(1980) , 10.1038/284067A0